brexanolone + methylprednisolone acetate

This is a **combination** of two pharmaceuticals: - **Brexanolone** is a neuroactive steroid and a positive allosteric modulator of the gamma-aminobutyric acid (GABAA) receptor, chemically identical to allopregnanolone. It is FDA-approved for the treatment of postpartum depression (PPD) in adults. Its mechanism involves enhancing GABAA receptor activity, which produces rapid and sustained antidepressant effects, and has also been shown to inhibit proinflammatory cytokines and reduce macrophage activation in PPD patients[1][4][5]. - **Methylprednisolone acetate** is a synthetic corticosteroid with strong anti-inflammatory and immunosuppressive properties. It is indicated for a range of conditions including autoimmune, allergic, inflammatory, and rheumatologic diseases, and is administered orally, intravenously, intramuscularly, intra-articularly, or intralesionally depending on clinical context. Its mechanism is mediated by gene regulation through the glucocorticoid receptor[2][6]. There is no evidence of a marketed or clinically tested product specifically combining both agents in a single formulation; each is used independently for their approved indications.